Science 37 Blockbuster SPAC Valuation Points To Growth In Decentralized Trials
Executive Summary
Expanding partnerships with CROs, the COVID-19 lockdown, an eager FDA and an industry desire for faster and more diverse clinical trial recruiting helped Science 37, a decentralized clinical trial company, nail down plans to go public. Science 37 CEO David Coman spoke with In Vivo about the reasons for going public via SPAC, and why decentralization is a “prerequisite to operating a clinical trial today.”
You may also be interested in...
Industry Is Moving Fast With Decentralized Trials, But Is It Too Fast?
Companies like Bayer and AstraZeneca are seeing what a difference decentralization makes as CVS is rapidly expanding its clinical research business.
Decentralized Trials Ease Enrollment In Rare Disease Studies
Panel discussion illustrated how decentralized approaches can expand the possibilities of studies in rare diseases, such as cancers with rare genomic alterations.
Smart Investing: Picking Winners In Gene Therapy
Venture capitalists and industry executives discussed strategies for placing smart bets on emerging gene therapy companies during a recent virtual panel.